Bill Calls for Disclosure of Drug-Company Gifts to Doctors - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Bill Calls for Disclosure of Drug-Company Gifts to Doctors


ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

Washington, DC (Sept. 6)—Senators Chuck Grassley (R-IA) and Herb Kohl (D-WI) introduced the Physician Payments Sunshine Act to require pharmaceutical and biologics manufacturers to report the payments, gifts, honoraria, and trips they give to doctors. The Act would apply to manufacturers with annual gross revenues of $100 million or more. It would provide penalties of $10,000–100,000 for each failure to report payments. In addition, the legislation would require the Secretary of Health and Human Services to clearly post payment information on a special website. Grassley said the legislation draws on similar initiatives in Minnesota, Vermont, Maine, and West Virginia. 

“Right now the public has no way to know whether a doctor’s been given money that might affect prescribing habits,” Grassley said in a press release. “Whether it’s dinner at a restaurant or tens of thousands of dollars or more in fees and travel, patients shouldn’t be in the dark about whether their doctors are getting money from drug and device makers.”

Senators Claire McCaskill (D-MO), a cosponsor of the bill, said in a press release, “By requiring drug companies … to report on their gifts to doctors, we are empowering patients to talk with their doctors about the drugs they are prescribed and to learn more about the influence of the pharmaceutical industry on the practice of medicine. I believe that by bringing light to these relationships, this legislation will go far in reducing big drug companies’ influence on the business of medicine.”

Senators Chuck Schumer (D-NY), Amy Klobuchar (D-MN), and Ted Kennedy (D-MA) also are original cosponsors of the Grassley–Kohl bill. Grassley is a ranking member of the Committee on Finance, where he has conducted oversight of educational grants awarded to doctors by drug companies. Kohl chairs the Special Committee on Aging. He held a hearing in June 2007 to examine the financial relationship between physicians and the pharmaceutical industry.

Click here for Grassley’s floor statement about the bill. Click here for information about the Aging Committee hearing.

ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Looking forward 10 years from now, what do you think will be the most significant change to drug development and manufacturing?
Fuller adoption of quality by design principles
Greater adoption of continuous manufacturing
A stronger movement to personalized medicine and the use of diagnostics with traditional pharmaceuticals
The rise of biologic-based drugs in commercial product portfolios and pipelines
Greater adoption of the preferred provider model in outsourcing
Fuller adoption of quality by design principles
22%
Greater adoption of continuous manufacturing
7%
A stronger movement to personalized medicine and the use of diagnostics with traditional pharmaceuticals
35%
The rise of biologic-based drugs in commercial product portfolios and pipelines
30%
Greater adoption of the preferred provider model in outsourcing
7%
View Results
Jim MillerOutsourcing OutlookJim Miller Channeling Steve Jobs
Patricia Van ArnumIngredients InsiderPatricia Van ArnumSeeking Chemocatalytic and Biocatalytic Solutions
Nathan JessopIndustry InsiderNathan Jessop Taxing Times for French Pharma
Lynn D. TorbeckStatistical Solutions Lynn D. TorbeckRepresentative Sampling
Report on Recent and Upcoming Single-Use Meetings
ICH Q11 Reaches Harmonization, Implementation is Next
Digital Signatures Growing as a Result of Part 11
Single-Cell Genomics Advancing Molecular Biology
Putting FDA’s “Process Validation” Guidance into Action
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here